Skelaxin Articles
King swings to loss in 1st qtr on Alpharma costs
12 May 2009
Stock Commentary - New York week to April 20, 2009
23 April 2009
Stock Commentary - New York week to Feb 16, 2009
23 February 2009
King to reduce its workforce 20%
16 February 2009
Stock Commentary - New York week to Feb 9, 2009
16 February 2009
King's profit drops 34% in 2nd-qtr 2008 to $43M
18 August 2008
Stock Commentary - New York week to Jan 14, 2008
21 January 2008
King's 2nd-qtr revenue rises 9%, net income falls
20 August 2007
Stock Commentary - New York - week to July 16, 2007
23 July 2007
King's 1st-qtr 2007 revenue increases 7%
21 May 2007
King's 3rd-qtr revenue drops 5% to $492M
27 November 2006
King sees 1st-qtr earnings drop 28% to $51M
29 May 2006
Stock Commentary - New York week to Mar 6, 2006
13 March 2006
King and Mutual to share metaxolone IP
19 December 2005
King Pharma 1st-qtr income rises 26%
23 May 2005
King's 3rd-qtr profit plunges, may restate
8 November 2004
Par Pharma buys Kali Labs in $135M deal
21 June 2004
King Pharma says FDA's Skelaxin decision "capricious"
22 March 2004
Stock Commentary - New York
22 March 2004
King 2003 revenues up 35%, but earnings slip
1 March 2004
Elan reports 34% drop in 2003 turnover
23 February 2004
Elan gets extra $70 million in deals
2 February 2004
King reins in 2003 profit forecasts
10 November 2003
King completes Elan acquisition at discount
23 June 2003
FTC drops enquiry into Elan's Skelaxin
19 May 2003
Stock Commentary - New York
12 May 2003
Lost revenues hit Elan as losses widen further
12 May 2003
Eon gets "no go" on generic Skelaxin
31 March 2003
King Pharma revises forecasts after Elan unit acquisitions
10 February 2003
Elan sells franchise to King for $850M
3 February 2003
Strong earnings growth for Ireland's Elan on healthy US sales
11 February 2002
Elan and Vernalis antimigraine drug wins US approval
12 November 2001
Elan net income leaps 89% in 1st qtr
24 April 2001
Elan full-year 2000 sales top $1.50 billion
29 January 2001
Liposome and Segix boost Elan revenues
21 July 2000
Hefty increase in 3rd qtr revenues at Elan
26 October 1999
Revenues Rise 63% At Ireland's Elan Corp In Third Quarter
27 October 1998
Showing 1-45 of 45 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
